PATENT CLAIM ANALYSIS

Application Number: 15893102
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "139100"]

Abstract:
Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leulcemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

Claim (Index 1):
A method of treating a hematological malignancy in a human patient, the method comprising administering to the patient an effective amount of an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5,\n wherein the method comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, the anti-LAG-3 antibody is administered as follows: (a) four doses of 20 mg anti-LAG-3 antibody; (b) four doses of 80 mg anti-LAG-3 antibody; (c) four doses of 240 mg anti-LAG-3 antibody; or (d) four doses of 800 mg anti-LAG-3 antibody.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.45714
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15021102', '15032919', '14437029', '15703126', '15166114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7668717773457886
- 35 USC 102 Novelty (BERT): 0.5707704369407036
- Combined Prediction Score: 0.7472616433052801
- Mean Citation Score: 420.279788
- Max Citation Score: 491.10278
- Similarity Product: 381.8659150180459

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test